cd44主要参与细胞黏附、迁移和肿瘤生物学，是肿瘤干细胞的标志物，具有重要的临床应用价值。 由于其在肿瘤干细胞中的高表达，CD44已成为肿瘤治疗的潜在靶点。

CD44 is a prominent activation marker which distinguishes memory and effector T cells from their naïve counterparts. It also plays a role in early T cell signaling events as it is bound to the lymphocyte-specific protein kinase and thereby enhances T cell receptor signalling.

cd44是一个公认的肿瘤干细胞膜表面标志物，参与肿瘤的启动，进展，转移等，靶向肿瘤干细胞一直都是肿瘤药物开发的重点。 针对CD44的单克隆抗体，阻断肽，CAR-T等都有企业参与研发。

CD44, a non-kinase transmembrane proteoglycan, is a single-chain glycoprotein encoded by one gene located on chromosome 11 in humans and on chromosome 2 in mice. The CD44 gene is comprised of 19 exons in humans and 20 in mice; a homolog of exon 6 …

2024年11月11日 · cd44 与 cd62l 作为 t 细胞表面极为关键的两种分子标记，以调控细胞迁移、黏附以及活化信号传导等多种机制的方式，深度参与到 t 细胞的活化、迁移以及记忆反应之中。

2008年10月10日 · Our results reveal a characteristic versatility of peptide recognition by the FERM domains from ERM proteins, suggest a possible mechanism by which the CD44 tail is released from the cytoskeleton for nuclear translocation by regulated intramembrane proteolysis, and provide a structural basis for Smad1 interactions with activated CD44 bound t...

2023年10月18日 · Currently, CD44 is an established cancer stem cell marker in several tumors, implying a central functional role in tumor biology. The present review aims to highlight the contribution of the CD44 short cytoplasmic tail, which is devoid of any enzymatic activity, in the extraordinary functional diversity of the receptor.

2023年4月28日 · Cluster of differentiation-44 (CD44) is a member of the non-kinase, single-span transmembrane glycoproteins family, which can contribute to cancer stem cells (CSCs)...

2025年3月28日 · b CD44 expression as median fluorescence intensity ... (“Comité de Protection des Personnes Ile de France 1”-N°IRB/IORG #: IORG0009918) under agreement number 2020-A01079-30.

2020年12月10日 · In this review, we focus on current data relevant to CD44, and outline CD44 structure, the regulation of CD44, functional properties of CD44 in carcinogenesis and cancer progression as well as the potential CD44-targeting therapy for cancer management.